74 5 ART for Anti-inflammation
Biniecka M, Kennedy A, Ng CT, Chang TC, Balogh E, Fox E, Veale DJ, Fearon U, O’Sulliban
JN (2011) Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative
stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis. Arthritis
Res Ther 13:R121
Cannon GW, Openshaw SJ, Hibbs JB Jr, Hoidal JR, Huecksteadt TP, Griffiths MM (1996)
NO production during adjuvant-induced and collagen-induced arthritis. Arthritis Rheum
39:1677–1684
Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, Zwerina J, Schett G (2010)
Mammalian target of rapamycin signaling is crucial for joint destruction in experimen-
tal arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis
Rheum 62:2294–2302
Chou LW, Wang J, Chang PL, Hsieh YL (2011) Hyaluronan modulates accumulation of hypoxia-
inducible factor-1 alpha, inducible NOS, and matrix metalloproteinase-3 in the synovium of
rat adjuvant-induced arthritis model. Arthritis Res Ther 13:R90
Cillero-Pastor B, Martin MA, Arenas J, Lopez-Armada MJ, Blanco FJ (2011) Effect of nitric
oxide on mitochondrial activity of human synovial cells. BMC Musculoskelet Disord 12:4
Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B (1980) Immunisation against het-
erologous type II collagen induces arthritis in mice. Nature 283:666–668
Cua DJ, Sherlock JP (2011) Gut microbiota strikes ‘‘back’’. Nat Med 17:1055–1056
Du JH, Zhang HD, Ma ZJ, Ji KM (2010) Artesunate induces oncosis-like cell death in vitro
and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother
Pharmacol 65:895–902
Eckmann L, Kagnoff MF (2005) Intestinal mucosal responses to microbial infection. Springer
Semin Immun 27:181–196
Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR (2001) The anti-malarial arte-
misinin is also active against cancer. Int J Oncol 18:767–773
Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME,
Volm M, Tew KD, Ross DD, Funk JO (2003) Molecular modes of action of artemisinin in
tumor cell lines. Mol Pharmacol 64:382–394
Farrell AJ, Blake DR, Palmar RMJ (1992) Increased concentrations of nitrite in synovial fluid
and serum samples suggest increased NO synthesis in rheumatic diseases. Ann Rheum Dis
51:1219–1222
FDA Alert (2011) http://www.drugs.com/fda/tumor-necrosis-factor-alpha-tnf-alphablockers-
label-change-boxed-warning-updated-risk-infection-13023.html, 7 Sept 2011
Fermor B, Christensen SE, Youn I, Cernanec JM, Davies CM, Weinberg JB (2007) Oxygen,
nitric oxide and articular cartilage. Euro Cell Mat 13:56–65
Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA (2003) M-CSF, TNFα and
RANK ligand promote osteoclasts survival by signaling through mTOR/S6 kinase. Cell
Death Differ 10:1165–1177
Han TH, Qamirani E, Nelson AG, Hyduke DR, Chaudhuri G, Kuo L, Liao JC (2003) Regulation
of nitric oxide consumption by hypoxic red blood cells. Proc Natl Acad Sci USA
100:12504–12509
He Y, Fan J, Lin H, Yang X, Ye Y, Liang L, Zhan Z, Dong X, Sun L, Xu H (2009) The anti-malaria
agent artemisinin inhibits expression of vascular endothelial growth factor and hypoxia inducible
factor 1 alpha in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int 31:53–60
Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F,
Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B (2009)
Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the
treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822–3829
Hultqvist M, Olofsson P, Gelderman KA, Holmberg J, Holmdahl R (2006) A new arthritis ther-
apy with oxidative burst inducers. PLoS Med 3:e348
Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C
(2009) Ectopic lymphoid structures support ongoing production of class-switched autoanti-
bodies in rheumatoid synovium. PLoS Med 6:e1